Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, discusses the current treatment landscape for patients with sickle cell disease (SCD). This includes hydroxyurea, pyruvate kinase activators, small molecules that increase the oxygen affinity of hemoglobin, antibody-based treatments, and recently approved gene therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
